Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

CARGO Therapeutics, Inc. Common Stock

CARGO Therapeutics is engineering best-in-class CAR T-cell therapy to overcome resistance to cancer treatment and address barriers to access so that more patients may benefit from potentially curative therapies. CARGO is on a mission to outsmart cancer by advancing a new generation of best-in-class chimeric antigen receptor (CAR) T-cell therapies. Despite advances made by commercially available autologous CARs, these treatments are curative for fewer than half of all cancer patients. In addition, far too many patients are unable to access these potentially curative therapies due to other challenges, including manufacturing, supply constraints, slow turnaround time and reimbursement hurdles. The team at CARGO is intensely focused on pursuing novel solutions to achieve better cancer treatment outcomes and experiences.

CARGO Therapeutics

Today we announced the appointment of Michael Ports, PhD, as Chief Scientific Officer. In this role at CARGO, Dr. Ports will be responsible for advancing our proprietary platform technologies and discovery-stage programs. Learn more: https://bit.ly/45QfufU

Today at the 8th CAR-TCR Summit in Boston, John Rossi, CARGO’s Vice President and Head of Translational Medicine, is presenting on strategies to deliver next generation engineered CAR T-cell therapy products to overcome resistance. John is also participating in a roundtable discussion on mechanisms of resistance and how to overcome them. Learn more here: https://lnkd.in/dn-KZVN 
#CARTCR #celltherapy #CART

Today we announced the addition of independent directors to our Board of Directors, bringing together an esteemed group of experienced life science leaders with expertise spanning finance, business operations, drug discovery and clinical development, including experts and pioneers in #CART therapies and #oncology. Learn more: https://bit.ly/47KuJIs

At CARGO, we are on a mission to advance next generation #CART therapies – and we are growing! We’re currently searching for a Medical Director to join our team. In this role, you’ll leverage your strong experience working across the clinical team to identify, influence and support priority initiatives while contributing to the leadership team and the advancement of CARGO cell therapy products. Review the job description here: https://lnkd.in/gRZYD2_3
#hiring #biotechjobs #celltherapy


Congratulations to our co-founder Crystal Mackall, MD, who was recently featured in an Endpoints News special report on 20 women reshaping biopharma for her pioneering work in the CAR T-cell therapy and oncology fields and her commitment to advocating for the next generation of women in biopharma! https://bit.ly/45qvyEz 
#CART #celltherapy #oncology

We are thrilled to participate in WuXi AppTec's BOLD: Innovation That Matters online series today! Our CEO Gina Simmons Chapman shares more about our work to advance #CART therapies for cancer during the spotlight session on the next wave of cancer therapeutics. Learn more and tune in here: https://bit.ly/43s85kM #TakingBOLDAction 

	Sep '22	Dec '22	Mar '23	Jun '23	Sep '23	Dec '23	Mar '24	Jun '24	Sep '24
revenue
cost of revenue								2.06M -
gross profit								-2.06M -
selling and marketing expenses
general and administrative expenses		1.77M -	2.69M 51.35%	3.87M 44.02%	6.48M 67.52%	7.89M 21.78%	10.30M 30.60%		11.18M -
selling general and administrative expenses		1.77M -	2.69M 51.35%	3.87M 44.02%	6.48M 67.52%	7.89M 21.78%	10.30M 30.60%	10.40M 0.93%	11.18M 7.51%
research and development expenses		9.23M -	12.56M 36.08%	13.93M 10.88%	22.23M 59.62%	27.07M 21.74%	30.50M 12.69%	36.86M 20.83%	35.93M 2.51%
other expenses		-6K -	-138K 2,200%	49K 135.51%	-6.76M 13,895.92%	2.88M 142.59%	-10K 100.35%
cost and expenses		11.01M -	15.25M 38.55%	17.80M 16.72%	28.71M 61.33%	34.96M 21.75%	40.81M 16.74%	49.32M 20.86%
operating expenses		11.01M -	15.25M 38.55%	17.80M 16.72%	28.71M 61.33%	34.96M 21.75%	40.81M 16.74%	47.26M 15.81%	47.11M 0.31%
interest expense		2.71M -	1.60M 40.77%
ebitda		-10.58M -	-14.60M 37.95%	-16.99M 16.41%	-34.42M 102.57%	-30.98M 10.01%	-33.96M 9.62%	-47.26M 39.17%	-47.11M 0.31%
operating income		-11.01M -	-15.25M 38.55%	-17.80M 16.72%	-28.71M 61.33%	-34.96M 21.75%	-40.81M 16.74%	-49.32M 20.86%	-47.11M 4.47%
depreciation and amortization		430K -	683K 58.84%	859K 25.77%	1.05M 22.12%	1.10M 4.96%	1.85M 68.39%	2.06M 11.17%
total other income expenses net		-36K -	4.00M 11,208.33%	49K 98.77%	-6.76M 13,895.92%	2.88M 142.59%	-10K 100.35%	4.97M 49,800%	5.20M 4.71%
income before tax		-13.75M -	-12.75M 7.29%	-17.85M 40.05%	-35.47M 98.69%	-32.08M 9.57%	-35.81M 11.64%	-44.35M 23.84%	-41.91M 5.50%
income tax expense		2.70M -	1.47M 45.74%	49K 96.66%	-6.76M 13,895.92%	2.88M 142.59%	-10K 100.35%
net income		-13.75M -	-12.75M 7.29%	-17.85M 40.05%	-35.47M 98.69%	-32.08M 9.57%	-35.81M 11.64%	-44.35M 23.84%	-41.91M 5.50%
weighted average shs out	19.47M -		38.67M -		38.67M -		41.00M -	43.34M 5.73%	47.66M 9.97%
weighted average shs out dil	19.47M -		38.67M -		38.67M -		41.00M -	43.34M 5.73%	47.66M 9.97%
eps	-0.63 -	0 100%	-0.33 Infinity%	0 100%	-0.92 Infinity%	0 100%	-0.87 Infinity%	-1.02 17.24%	-0.88 13.73%
epsdiluted	-0.63 -	0 100%	-0.33 Infinity%	0 100%	-0.92 Infinity%	0 100%	-0.87 Infinity%	-1.02 17.24%	-0.88 13.73%

CRGX

COM:CARGO-TX

CARGO Therapeutics

Last Close

15.73

22/11 21:00

Market Cap

747.03M

Beta: -

Volume Today

156.59K

Avg: -

Preview